Mepolizumab for the treatment of patients with severe hypereosinophilic syndrome

NICE

29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of mepolizumab in the NHS in England.

NICE is unable to make a recommendation on the use of mepolizumab for the treatment of patients with severe hypereosinophilic syndrome because GSK did not provide an evidence submission.

Read NICE technology appraisal

Michael Wonder

Posted by:

Michael Wonder